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Abstract: 
ATP-dependent Clp protease (ClpP) is a core unit of a major bacterial protease complex employing as a new attractive drug target for that 
isolates, which are resistant to antibiotics. Mycobacterium tuberculosis, a gram-positive bacterium, is one of the major causes of hospital acquired 
infections. ClpP in Mycobacterium tuberculosis is usually tightly regulated and strictly requires a member of the family of Clp-ATPase and often 
further accessory proteins for proteolytic activation. Inhibition of ClpP eliminates these safeguards and start proteolytic degradation. Such 
uncontrolled proteolysis leads to inhibition of bacterial cell division and eventually cell death. In order to inhibit Clp protease, at first three 
dimensional structure model of ClpP in Mycobacterium tuberculosis was determined by comparative homology modeling program MODELLER 
based on crystal structure of the proteolytic component of the caseinolytic Clp protease (ClpP) from E. coli as a template protein and has 55% 
sequence identity with ClpP protein. The computed model’s energy was minimized and validated using PROCHECK to obtain a stable model 
structure and is submitted in Protein Model Database (PMDB-ID: PM0075741). Stable model was further used for virtual screening against 
marine derived bioactive compound database through molecular docking studies using AutoDock 3.05. The docked complexes were validated 
and enumerated based on the AutoDock Scoring function to pick out the best marine inhibitors based on docked Energy. Thus from the entire 186 
Marine compounds which were Docked, we got best 5 of them with optimal docked Energy (Ara-A: -14.31 kcal/mol, Dysinosin C: - 
14.90kcal/mol, Nagelamide A: -20.49 kcal/mol, Strobilin: -8.02 kcal/mol, Manoalide: -8.81 kcal/mol). Further the five best-docked complexes 
were analyzed through Python Molecular Viewer software for their interaction studies. Thus from the Complex scoring and binding ability its 
deciphered that these Marine compounds could be promising inhibitors for ClpP as Drug target yet pharmacological studies have to confirm it. 
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Background: 
Bacterial pathogens have evolved numerous defense mechanisms 
against antimicrobial agents, and resistance to old and new produced 
drugs are on the rise. The alarming increase of antibiotic-resistant 
bacterial pathogens points to the need for novel therapeutic approaches 
to combat infection.Tuberculosis (TB) is an infectious disease that is 
caused by the gram-positive bacteria known as Mycobacterium 
tuberculosis. It is the major causes of death from an infections disease 
in the world resulting in an estimated 2 billion people have latent TB, 
while another 3 million people worldwide die of TB each year [1]. 
This alarming increase of bacterial pathogens points to the need for 
novel therapeutic approaches to combat infection. The ATP-dependent 
Clp protease of Mycobacterium tuberculosis CDC1551 consists of two 
subunits, the ClpP subunit which is capable of degrading peptides in 
energy-dependent manner and ClpX, which possesses ATPase activity 
and activates the proteolytic activity of ClpP in vitro. ClpP is a core 
unit of a major bacterial protease complex imploying as a new drug 
target for that isolates, which are resistant to antibiotics. ClpP is 
usually tightly regulated and strictly requires a member of the family 
of Clp-ATPase and often further accessory proteins for proteolytic 
activation. Binding of inhibitor with ClpP eliminates these safeguards. 
The inhibitor-activated ClpP core is capable of proteolytic degradation 
in the absence of the regulatory Clp-ATPases. Such uncontrolled 
proteolysis leads to inhibition of bacterial cell division and eventually 
cell death [2]. ClpP is a key catalyst in proteolytic activation and a 
promising attractive drug target for novel antibiotics. 
 
In this study, we targeted the ClpP and proposed the three-dimensional 
structure model, determined by comparative homology modeling. 
Crystal structure of the proteolytic component of the caseinolytic Clp 
protease (ClpP) from E. coli having 55% identity in amino acid 
sequence with ClpP was used as a template protein for homology 
modeling. Stereochemical property of the model was checked. Model 
was further used for virtual screening against Marine Compound 
Database (MCDB) [3,4]. Since inhibitor of ClpP can be a good 
candidate of the new antimicrobial drug, we studied interactions 
between the ClpP with Inhibitors 
 
Methodology: 
Model building 
The single amino acid sequence of ATP-dependent Clp protease 
proteolytic subunit in Mycobacterium tuberculosis CDC1551 
(Accession No: NP_337022, Version: NP_337022.1, GI: 15841985) 
was retrieved from protein sequence database sited at NCBI [5] and 
taken as target protein sequence. The modeling of 3D structure of 
target protein followed a stepwise procedure, starting with a template 
structure search from PDB (protein databank) [6], related to the target 
sequence using BLASTP [7]. From a number of hits, a potential 
template structure (PDB-ID: 1TYF), representing the crystal structure 
of the proteolytic component of the caseinolytic Clp protease (ClpP) 
from E. coli was taken as template for model building. The template 
and target sequences were aligned using the align2d script available in 
comparative protein modeling program MODELLER9v6 [8].  Based 
on the alignment, five comparative models of the target sequence were 
built by MODELLER, applying the default model building routine 
‘model’ with fast refinement. In the first step of model building, 
distance and dihedral angle restraints on the target sequence were 
derived from its alignment with the template 3D-structure. 
 
Evaluation of model 
The best model can be selected by picking the model with the lowest 
value of the Modeller objective function and DOPE (Discrete 
Optimization Protein) score from a collection of models built by 
MODELLER. Modeller objective function and DOPE score are the 
statistical parameter for assessment of model using the standard 
Modeller Energy function. The Stereochemical qualities of the models 
are checked by PROCHECK [9]. 
 
Active site analysis 
After the final model was built, the possible Active site residues of 
ClpP in Mycobacterium tuberculosis was identified on the basis of 
CSA (Catalytic Site Atlas) [10] entry of PDB code of 1TYF contains a 
GLY-SER -MET -HIS-ASP Catalytic triad [11].  These residues of 
active site are conserved in various bacterial ClpP proteins. Thus the 
active site residues of ClpP in Mycobacterium tuberculosis have 
GLY68 - SER98 - MET99 - HIS123 -ASP172 Catalytic triad. Bioinformation   open access 
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Figure 1: Docking model of (a) Ara-A inhibitor with active site residues of ClpP. (b) dysinosin C inhibitor with active site residues of ClpP. (c) 
Manoalide inhibitor with active site residues of ClpP. (d) Nagelamide inhibitor with active site residues of ClpP. (e) Strobilin inhibitor with active 
site residues of ClpP. Hydrogen bond between inhibitor and residue is represented by green line in each case. 
 
Ligand generation and optimization 
The 2D structures of ligands used in this study were downloaded from 
Marine Compound Database (MCDB) [3,4]. The downloaded ligands in 
the mol (MDL MOL) format were first converted to the hin 
(HyperChem) format using OpenBabel [12].  The 2D structures of 
ligands were converted to 3D structures using the HyperChem7.5 
software [13]. All modeling procedures, including energy minimization 
and molecular dynamics, were also performed using the HyperChem. 
Energy calculations were carried out using the AMBER force field. 
Optimized molecular structure using conjugate gradient method Polak-
Ribiere until the maximum energy derivative was lower than 
0.1kcal/A
omol in order to obtain a correct geometry. Further the 
optimize ligands in hin format were converted to the PDB (Protein 
Databank) format using OpenBabel. 
 
Virtual screening 
Virtual screening of the entire 186 marine compounds of MCDB [3,4] 
against ClpP protein structure, determined by comparative homology Bioinformation   open access 
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modeling, were done using molecular docking program AutoDock 3.05 
[14]. The Kollman charges and the solvation term were then added to 
the protein structure using the AutoDockTool [15].  A grid-box was 
generated that was large enough to cover the entire protein catalytic site 
and accommodate ligands to move freely. AutoDock3.05 and a 
Lamarckian Genetic Algorithm (LGA) were used for protein-fixed 
ligand-flexible docking calculations. Thirty search attempts (ga_run 
parameter) were performed for each ligand. The maximum number of 
energy evaluations before the termination of LGA run was 250000 and 
the maximum number of generations of the LGA run before termination 
was 27000. Other docking parameters were set to the software’s default 
values. After docking, the ligands were ranked according to their 
docked energy as implemented in the AutoDock 3.05 program. 
 
Results and discussion: 
Five models of ClpP were generated by MODELLER using crystal 
structure of the proteolytic component of the caseinolytic Clp protease 
(ClpP) from E.coli [PDB-ID: 1TYF] as a template protein for homology 
modeling. In order to select the best model, lowest value of Modeller 
objective function and DOPE score are used and further checked the 
structural validity by PROCHECK and is submitted in Protein Model 
Database (PMDB) [16].  3D structure of all the 186 compound of 
MCDB  [3, 4] were generated and subjected to energy minimization 
using conjugate gradient algorithm through HyperChem7.5 software 
[13]. Docking of these optimized compounds against modeled ClpP at 
the catalytic site residues were performed by AutoDock3.05 [14]. Out 
of 186 docked complexes, we got 5 best docked marine compounds 
having lowest docked energy and Root mean square deviation from a 
reference structure are shown in table 1 (see supplementary material) 
and rest of the data not shown in this work. Five best docked complexes 
were analyzed through Python Molecular Viewer [17]  for their 
interaction study shown in Figure 1 (a, b, c, d, e). It is evident from this 
analysis that the best marine inhibitors are located in the center of the 
active site and is stabilized by hydrogen bonding interactions. 
 
Conclusion:  
ClpP is one of the most recent potent Drug target for tuberculosis. In 
this work, we have constructed a 3D model of ClpP, using the 
MODELLER software and obtained a refined model after energy 
minimization. The final refined model was further assessed by 
PROCHECK program, and the results show that the model was stable 
and reliable. The stable model was further used for Virtual Docking of 
Marine Compounds. Docking results indicate that out of 186 Marine 
compounds, there were five inhibitory compounds for ClpP as target for 
tuberculosis. As it’s well known, hydrogen bonding plays an important 
role for the structure and function of biological molecules, especially 
for inhibition in a complex. Thus our study confirms Ara-A, Dysinosin 
C, Manoalide, Nagelamide A and Strobilin are potential inhibitors for 
ClpP as target for tuberculosis forming a hydrogen bonding and with 
non-bonded interaction to act as a drug candidates yet Pharmacological 
study will yet confirm it to be promising. 
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Supplementary material: 
 
Table 1: Docked marine compounds 
S. 
No. 
Marine 
Compound 
name 
IUPAC name  Molecular 
formula and Mol. 
Wt. 
Docked 
Energy 
(kcal/mol) 
Ref 
RMS 
1      Ara-A 
 
(2R, 3S, 4S, 5R)-2-(6-minopurin-9-yl)-5-(hydroxymethyl) 
tetrahydrofuran-3, 4-diol 
C10H13N5O4 
267.2413 
-14.31 16.03 
2 Dysinosin  C 
 
[3-[[1-[(2S,3aR,5S,6S,7aS)-2-[2-[1-(diaminomethylene)-2,5-
dihydropyrrol-1-ium-3- yl]ethylcarbamoyl]-5,6-dihydroxy-
2,3,3a,4,5,6,7,7a-octahydroindole-1-carbonyl]-2-methyl-
propyl]amino]-2-methoxy-3-oxo-propyl] sulfate 
C25H42N6O10S 
618.7002 
 
-14.90 14.25 
3 Manoalide 
 
5-hydroxy-4-[(2R,6R)-6-hydroxy-5-[(E)-4-methyl-6-(2,6,6-
trimethyl-1-cyclohexenyl)hex-3-enyl]-3,6-dihydro-2H-pyran-2-yl]-
5H-furan-2-one 
C25H36O5 
416.5503 
 
-8.81 15.05 
4 Nagelamide  A 
 
N-[3-[2-amino-5-[(E)-3-[(4,5-dibromo1H-pyrrole-2-
carbonyl)amino]prop-1-enyl]-3H-imidazol-4-yl]-3-(2-amino-3H-
imidazol-4-yl)propyl]-4,5-dibromo-1H-pyrrole-2-carboxamide 
C22H22Br4N10O2 
778.0919 
 
-20.49 13.36 
5 Strobilin  (5Z)-5-[(5E,9E)-13-(3-furyl)-2,6,10-trimethyl-trideca-5,9-
dienylidene]-4-hydroxy-3-methyl-furan-2-one 
C25H34O4 
398.5351 
-8.02 15.6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 